Benralizumab for pulmonary disease, chronic obstructive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Sep 2019: Trial registered, NCT04098718
  2. 29 Mar 2021: Trial started, NCT04098718

The trials

NCT04098718: Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)

State
State not given
Phase
Phase 2
People
158 planned
Started
29 Mar 2021
Primary completion
19 Feb 2024
Arms
Benralizumab SC + PO placebo, Benralizumab SC + PO prednisolone
Results
None posted
  1. 23 Sep 2019: Trial registered
  2. 29 Mar 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Benralizumab 30 MG/ML [Fasenra], Fasenra.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.